Regeneron Pharmaceuticals Inc (REGN)vsSionna Therapeutics, Inc. Common Stock (SION)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
SION
Sionna Therapeutics, Inc. Common Stock
$37.08
+6.67%
HEALTHCARE · Cap: $1.67B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
SION
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Intrinsic value data unavailable for SION.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : SION
The strongest argument for SION centers on Debt/Equity.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : SION
The primary concerns for SION are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 23/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Sionna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sionna Therapeutics, Inc. is an innovative biotechnology company specializing in the development of therapies for neurodegenerative diseases, with a particular emphasis on addressing protein misfolding and aggregation associated with conditions such as Alzheimer's and Parkinson's diseases. Leveraging its proprietary technologies and a robust scientific foundation, Sionna is building a promising pipeline aimed at fulfilling the substantial unmet medical needs within this therapeutic area. The company's commitment to research and development, coupled with strategic collaborations, positions it as a significant player in the biopharmaceutical landscape, focused on improving the quality of life for patients suffering from these challenging neurological disorders.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?